AbbVie对种族平等的承诺

AbbVie believes our clinical trials should reflect the populations we serve as we aim to help patients live healthier, longer lives. Ensuring diversity means we can better meet the needs of our patients both today and tomorrow. We are committed to researching and bringing treatment options for diseases that affect patients around the world, including groups of patients who historically have been underserved.
\r\n
\r\nAs part of our dedication, AbbVie is committed to being an industry leader in improving clinical research diversity. We rely on real-world data and evidence to guide our diversity and inclusion strategies to ensure participation in AbbVie-sponsored clinical trials appropriately represents patients living with the diseases we are studying. We have been and will continue to analyze our clinical trials to ensure they reflect a diversity in race, ethnicity, age, and gender. To this end, our continuing commitment is as follows:

\r\n

\r\n
• Evaluating our clinical trial protocol eligibility criteria against real-world datasets to ensure we are designing inclusive study protocols, enabling under-represented populations to volunteer for our clinical trials
\r\n
• Analyzing and ensuring the age, gender, race, and ethnicity of those enrolled in our clinical trials appropriately reflects the age, gender, race, and ethnicity of the patient population we are studying. If diversity gaps are identified within indications in our portfolio, we will create a tailored plan to address specific gaps. This plan may include enhanced community partnerships, clinical research staff education, investigator trainings, new site selection strategies, and targeted patient outreach.
\r\n
• Routinely re-assessing clinical study demographics to determine if our efforts to ensure participation of under-represented populations have made an impact, pivoting to different strategies if necessary.
\r\n
• Continuing to refine our clinical trial diversity and inclusion strategies based on analytics and ensuring every team has access to regional indication demographics, including AbbVie resources to help resolve previously identified diversity gaps.
\r\n

\r\n"}}" id="text-e511937c68" class="cmp-text">

AbbVie相信我们的临床试验应该反映人口我们作为我们的目标是帮助病人生活更健康,延长生命。确保多样性意味着我们可以更好的满足病人的需要今天和明天。我们致力于研究和疾病治疗方案影响世界各地的病人,包括组患者历来是缺医少药。

作为我们的奉献精神的一部分,AbbVie致力于成为行业的领导者在改善临床研究的多样性。我们依靠真实的数据和证据来指导我们的多样性和包容性策略以确保适当参与AbbVie-sponsored临床试验代表了我们正在研究疾病患者的生活。我们已经并将继续分析我们的临床试验,以确保它们反映出种族多样性,种族,年龄和性别。为此,我们继续承诺如下:

• 评估我们的临床试验协议合格标准对现实世界的数据集,以确保我们正在设计包容性研究协议,使弱势群体志愿者为我们的临床试验
• 分析和确保年龄,性别,种族,和民族的登记在我们的临床试验适当反映了年龄、性别、种族和种族病人的人口我们正在研究。如果多样性差异中发现迹象表明在我们的投资组合,我们将创建一个定制的计划来解决特定的差距。这个计划可能包括增强社区伙伴关系,临床研究人员教育、人员培训,新选址策略,有针对性的病人接触。
• 定期评估临床研究人口结构来确定我们的努力确保弱势群体的参与,产生了影响,旋转,如果需要不同的策略。
• 继续完善我们的临床试验多样性和包容性的策略基于分析,确保每一个团队区域显示人口,包括AbbVie资源来帮助解决之前识别多样性差异。

Black Americans face significant health disparities as a result of systemic inequalities, and as a biopharmaceutical company, it is our moral obligation to do all that we can to help reduce these disparities.
\r\n
\r\nSince we became a company, we have developed new medicines and treatments for diseases that disproportionately impact Black communities, including:

\r\n

\r\n
• A cure for Hepatitis C, as Black men and women aged 60 and older are 10 times more likely to be chronically infected with, compared to other Americans.
\r\n
• The first oral medication for the management of heavy menstrual bleeding due to uterine fibroids. Black women suffer from a higher cumulative risk of uterine fibroids, a threefold greater incidence and relative risk of fibroids, and an earlier age of onset.
\r\n
• An oral treatment for chronic lymphocytic leukemia (CLL). Black patients with CLL are almost twice as likely to die from a CLL-related complication in the first 5 years after diagnosis as are Caucasian patients with CLL.
\r\n

\r\n

But we are far from finished. We are working to develop new treatments that will significantly advance the standard of care for a number of diseases.

\r\n"}}" id="text-7d1bc42b59" class="cmp-text">

美国黑人面临重大健康差异由于系统性的不平等,生物制药公司,这是我们的道德义务尽我们所能帮助减少这些差异。

自从我们成为了一个公司,我们已经开发出新的药物和治疗疾病,黑人社区不成比例的影响,包括:

• 治疗丙型肝炎,黑人男性和60岁以上的女性10倍慢性感染,与其他美国人相比。
• 第一个口服药物治疗重型月经出血的管理由于子宫肌瘤。黑人女性遭受从一个更高的累积风险的子宫肌瘤,三倍大的子宫肌瘤的发病率和相对风险,和早期发病的年龄。
• 口服治疗慢性淋巴细胞白血病(CLL)。黑色的慢性淋巴细胞白血病患者几乎两倍死从CLL-related并发症在确诊后的头5年,是白种人的慢性淋巴细胞白血病患者。

但我们还远没有完成。我们正在努力开发新的治疗方法,将大大推进标准治疗的疾病。